Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics insider Patrick Burnett filed to sell 15,000 shares of common stock of Arcutis Biotherapeutics through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise dated January 12, 2024. In the prior three months, Burnett sold 955 shares of common stock on August 3, 2026 for $24,941.54.
State Street Corporation reported beneficial ownership of common stock of Arcutis Biotherapeutics, Inc.. State Street and its investment adviser affiliates collectively beneficially owned 5,822,840 shares of Arcutis common stock, representing 4.7% of the class as of the reporting date.
State Street reported no sole voting or dispositive power over Arcutis shares. It reported shared voting power over 5,507,182 shares and shared dispositive power over 5,822,840 shares, indicating these positions are managed across listed advisory subsidiaries, including SSGA Funds Management, Inc. and several State Street Global Advisors entities. The filing is made on the basis of ownership of 5 percent or less of the class.
Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett reported selling 955 shares of common stock on 2026-08-03 at a weighted-average price of $26.1168 per share, in multiple trades between $25.72 and $26.69. Footnotes state the sale was solely to cover tax withholding obligations arising from vesting Restricted Stock Units and was effected pursuant to a Rule 10b5-1 trading plan. After this transaction, Burnett directly owns 119,289 shares of Arcutis common stock.
Arcutis Biotherapeutics executive Masaru Matsuda, EVP and Chief Legal Officer, reported selling 1,230 shares of common stock on August 3, 2026 at a weighted average price of $26.1168 per share under a Rule 10b5-1 trading plan. The sale represents shares sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units, with trade prices ranging from $25.72 to $26.69. Following this transaction, Matsuda directly holds 126,171 shares, including 712 shares acquired through the company’s Employee Stock Purchase Plan.
Arcutis Biotherapeutics President and CEO Todd Watanabe sold 4375.0000 shares of common stock on August 3, 2026 at a weighted average price of $26.1168 (with individual prices from $25.72 to $26.69) to cover tax withholding obligations arising from the vesting of Restricted Stock Units, in a transaction reported under a Rule 10b5-1 trading plan. After this sale he directly held 717203.0000 shares, including 823 acquired through the Employee Stock Purchase Plan, and additional shares are held indirectly through trusts and Watanabe Ventures, LLC, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Arcutis Biotherapeutics reported strong results for the quarter ended June 30, 2026, with total product revenue, net, of $129,861 (in thousands), a 59% increase year over year. Net income was $15,009 (in thousands), compared with a net loss in the prior-year quarter, and diluted EPS was $0.11.
ZORYVE foam contributed $67,377 (in thousands), while ZORYVE cream 0.3%, 0.15%, and 0.05% contributed $35,327, $24,231, and $2,926 (each in thousands) in the quarter. For the first six months of 2026, total product revenue, net, reached $235,259 (in thousands), and net income was $3.7 million.
Cash, cash equivalents, restricted cash, and marketable securities totaled $238.9 million at June 30, 2026, against $100.0 million of debt, and the company believes these resources will meet projected operating requirements for at least 12 months. Arcutis advanced its dermatology portfolio, including an sNDA for infant atopic dermatitis with a PDUFA date of February 23, 2027 and a Phase 1a/1b trial of ARQ-234.
Arcutis Biotherapeutics reported strong second quarter 2026 results, with net product revenue of $129.9 million, up 59% year over year and 23% sequentially, driven by demand for ZORYVE. The company generated net income of $15.0 million, or $0.11 per share, and $12.6 million of operating cash flow. Cash, cash equivalents, restricted cash, and marketable securities totaled $238.9 million as of June 30, 2026. Full-year 2026 net product sales guidance was raised to $525 million–$540 million.
Commercially, ZORYVE revenues reached $35.3 million for cream 0.3%, $24.2 million for cream 0.15%, $2.9 million for cream 0.05%, and $67.4 million for foam 0.3%. The company gained FDA approval to expand ZORYVE cream 0.3% to plaque psoriasis in children down to age 2, and the FDA accepted an sNDA for ZORYVE cream 0.05% in infants with atopic dermatitis, with a PDUFA target date of February 23, 2027. Phase 2 studies in vitiligo and hidradenitis suppurativa and a Phase 1a/1b study of ARQ-234 are progressing.
Arcutis also announced leadership changes. Chief commercial officer L. Todd Edwards will resign effective August 21, 2026, to pursue an external opportunity, supported by a transition payment of up to $175,000. Robert Lisicki will serve as interim executive vice president from August 17, 2026 and interim chief commercial officer from August 21, 2026. Under his employment arrangements, he will receive a $555,000 annual base salary, a target bonus equal to 50% of base salary, options to purchase 145,000 shares, and 55,000 restricted stock units, with standard vesting and change-in-control severance protections.
Masaru Matsuda filed a notice of proposed sale of 1,230 shares of Arcutis Biotherapeutics common stock. The shares are to be sold through Merrill Lynch on the NASDAQ, with an anticipated sale date of August 3, 2026, and originated from Restricted Stock Vesting on August 1, 2026. Over the prior three months, Matsuda sold 8,256 shares of common stock on May 4, 2026, for proceeds of $192,415.53.
Arcutis Biotherapeutics insider Todd F. Watanabe filed to sell common stock under Rule 144. The planned sale covers 4,375 shares of common stock that became eligible for sale through restricted stock vesting on August 1, 2026. The shares are listed on NASDAQ and are held through a Merrill Lynch account in Columbus, Ohio.
Within the preceding three months, Watanabe previously sold 3,172 common shares on May 4, 2026 for total proceeds of $74,892.82. This filing provides advance notice of the planned disposition of additional shares.
Patrick Burnett filed to sell common stock of Arcutis Biotherapeutics under a planned transaction. The filing lists 955 shares of common stock to be sold through Merrill Lynch, with an anticipated sale date of 08/03/2026 on NASDAQ.
The filing also references the source of these shares as restricted stock vesting on 08/01/2026 and discloses prior sales over the past three months: 684 shares for 16,149.65 on 05/04/2026 and 222 shares for 4,673.10 on 05/11/2026.